# Safety Tolerability & Pharmacokinetics of Co-administered Single Doses of OZ439 & Piperaquine to Healthy Subjects

> **NCT01660022** · PHASE1 · COMPLETED · sponsor: **Medicines for Malaria Venture** · enrollment: 59 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** 100mg OZ439 single oral dose
- **DRUG:** Placebo
- **DRUG:** 300 mg OZ439 single oral dose
- **DRUG:** 160mg Piperaquine single oral dose
- **DRUG:** 480mg Piperaquine single oral dose
- **DRUG:** 1440mg Piperaquine single oral dose
- **DRUG:** 800 mg OZ439 single oral dose

## Key facts

- **NCT ID:** NCT01660022
- **Lead sponsor:** Medicines for Malaria Venture
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2015-01-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01660022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01660022, "Safety Tolerability & Pharmacokinetics of Co-administered Single Doses of OZ439 & Piperaquine to Healthy Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01660022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*